Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:14:07 UTC, with 26 holding rows worth $1,634,072,026.

Accession
0001420506-26-002879
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 26 entries on the cover page, a total value of $1,634,072,026 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,634,072,026 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
REVOLUTION MEDICINES INC COM76155X100Stock1,961,795$402,678,042dollars as filed
LIQUIDIA CORPORATION COM NEW53635D202Stock8,118,892$245,677,672dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,557,924$154,265,634dollars as filed
VAXCYTE INC COM92243G108Stock2,188,636$124,533,388dollars as filed
EXELIXIS INC COM30161Q104Stock1,553,262$90,726,033dollars as filed
TANGO THERAPEUTICS INC87583X109COM2,501,246$62,406,088dollars as filed
ADMA BIOLOGICS INC000899104COM5,875,007$58,926,320dollars as filed
IMMUNOCORE HLDGS PLC ADS45258D105ADR1,672,141$50,649,151dollars as filed
AVALO THERAPEUTICS INC05338F306COMMON STOCK3,268,303$50,103,085dollars as filed
LB PHARMACEUTICALS INC50180M108COMMON STOCK1,509,621$49,621,242dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM2,193,981$45,174,069dollars as filed
VOR BIOPHARMA INC929033207COMMON STOCK1,925,066$36,730,259dollars as filed
INVENTIVA SA46124U107ADS9,185,935$33,896,100dollars as filed
OPUS GENETICS INC67577R102COMMON STOCK5,960,972$28,851,104dollars as filed
AURA BIOSCIENCES INC05153U107COMMON STOCK4,590,253$28,826,789dollars as filed
ANIKA THERAPEUTICS INC035255108COM1,435,130$28,214,656dollars as filed
SAB BIOTHERAPEUTICS INC78397T202COMMON STOCK8,736,898$27,695,967dollars as filed
SAGIMET BIOSCIENCES INC A786700104COMMON STOCK2,794,484$27,609,502dollars as filed
FAETH THERAPEUTICS INC81728A207COM NEW890,210$26,474,845dollars as filed
TYRA BIOSCIENCES INC90240B106COMMON STOCK910,749$19,918,081dollars as filed
Obsidian Therapeutics, Inc.67448A106Common Stock, $0.0001 par value per share886,281$12,168,638dollars as filed
EUPRAXIA PHARMACEUTICALS INC29842P105COM 298736 AL 3 EURONET WORLDWIDE INC NOTE 0.750% 3/11,163,010$10,583,391dollars as filed
ARTIVA BIOTHERAPEUTICS INC04317A107COM1,481,043$10,545,026dollars as filed
VERRICA PHARMACEUTICALS INC92511W207COM SHS923,910$4,430,148dollars as filed
TCGX ACQUISITION CORPG8708J109COM200,000$2,502,000dollars as filed
CELLECTAR BIOSCIENCES INC15117F880COM NEW469,998$864,796dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-26-002879this filing2026-11-16